Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake
This article was originally published in The Pink Sheet Daily
Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.
You may also be interested in...
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.